IMPORTANT: Read the Prep & Injection Guide for proper reconstitution, syringe sizing, and injection protocols. Mistakes here can compromise your research.
K-Copper combines GHK-Cu (copper peptide, 50 mg) and KPV (20 mg) in a single vial. GHK-Cu is a naturally occurring copper-binding tripeptide studied for skin regeneration, collagen and elastin synthesis, wound healing, and antioxidant activity. KPV is the C-terminal tripeptide fragment of alpha-MSH, researched for its potent anti-inflammatory activity in skin and gut tissue without the pigmentation effects of the full hormone. Together the pair is researched for calming inflammation while promoting tissue repair, skin quality, and wound healing.
— GHK-Cu 50 mg + KPV 20 mg Blend Vial —
Reconstitute: Add 3.0 mL (300 units) bacteriostatic water.
Administration: Subcutaneous injection.
Timing: May be dosed at any time of day or night; fasting is not required.
Storage: Lyophilized: freeze at −20 °C; reconstituted: refrigerate at 2–8 °C, avoid freeze-thaw cycles.
Schedule: Once-daily injections.
Cycle Length: 4–6 week cycle, followed by a 4–6 week washout period.
Goal: Support skin regeneration, wound healing, and inflammation control based on preclinical evidence.
Standard Protocol
| Phase | Dose | Syringe (U-100) |
|---|---|---|
| Initial (titration) | ~667 mcg GHK-Cu + ~267 mcg KPV | 4 units (0.04 mL), 1x/day |
| Standard (if well tolerated) | ~1,333 mcg GHK-Cu + ~533 mcg KPV | 8 units (0.08 mL), 1x/day for duration of cycle |
Note: Begin at 4 units once per day. If no adverse side effects occur, increase to the standard dose of 8 units once per day for the remainder of the cycle.
- Stimulates collagen and elastin synthesis for improved skin firmness and elasticity (GHK-Cu).
- Accelerates wound healing and tissue remodeling.
- Potent anti-inflammatory activity in skin and gut tissue (KPV).
- Antioxidant and free-radical scavenging activity.
- May improve skin texture, tone, and the appearance of fine lines.
- Studied for hair follicle support and scalp health (GHK-Cu).
- KPV is researched for calming inflammatory skin conditions and supporting gut-lining health.
- May reduce redness, irritation, and post-procedure inflammation.
While side effects are not common, you may experience:
- Irritation, redness, or itching at the injection site
- Headaches
- Nausea
- Fatigue or lethargy
- Dizziness (copper sensitivity at higher doses)
- Do not use when pregnant or nursing.
- Do not use with Wilson’s disease or other copper-metabolism disorders (GHK-Cu delivers copper).
- Do not use with active cancer — GHK-Cu promotes angiogenesis and tissue growth signaling.
- Exercise caution with severe kidney or liver disease.
- Discontinue if signs of an allergic reaction occur.
K-Copper is itself a stack of GHK-Cu and KPV. Common research pairings to extend it include:
- BPC-157 – For systemic tissue repair and gut support alongside KPV
- TB-500 – For flexibility, cell migration, and reduced scar formation
- Glow-type blends (GHK-Cu + BPC-157 + TB-500) – For comprehensive skin and tissue protocols
PubMed-linked citations for verification. Many studies are animal/in-vitro.
- GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int. 2015;2015:648108. PMID: 26236730
- Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. 2018;19(7):1987. PMID: 30011867
- PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-78. PMID: 18061177
- The copper tripeptide GHK-Cu: biological activity and skin remodeling (review of clinical and experimental data on copper peptides in dermatology). Pickart L, et al.
- KPV (Lys-Pro-Val), the C-terminal tripeptide of alpha-MSH, exerts anti-inflammatory activity in experimental models of inflammation. Multiple preclinical studies of alpha-MSH-derived tripeptides.
Research Use Only. All information on this page is for educational purposes only and is not medical advice. PepSherpa does not sell peptides. Consult a licensed healthcare provider before making any health decisions. Many of the studies cited are preclinical (animal/in-vitro).
